Pancreatic Cancer Research

ResearcherShanghai University of Traditional Chinese MedicineActive in the last 2 years

Hong‐Xi Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6238-4511; OpenAlex author ID A5034735808. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 4 papers

Papers 7

  1. Neobractatin and Trametinib Synergistically Induce Apoptosis and Gasdermin E-Dependent Pyroptosis in Pancreatic Cancer Cells. Last author DOI 10.1002/mco2.70250↗
  2. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. Co-author DOI 10.1016/j.jare.2024.09.006↗
  3. Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Last author DOI 10.1038/s41419-025-07495-2↗
  4. Correction: Pulsatilla Decoction and its bioactive component β-peltatin induce G2/M cell cycle arrest and apoptosis in pancreatic cancer. Last author DOI 10.1186/s13020-025-01207-w↗
  5. Pulsatilla Decoction and its bioactive component β-peltatin induce G2/M cell cycle arrest and apoptosis in pancreatic cancer. Last author DOI 10.1186/s13020-023-00774-0↗
  6. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. First author DOI 10.1186/s13046-022-02270-z↗
  7. Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Last author DOI 10.1038/s41419-018-0574-1↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yang Li · 3 shared papers, 2018–2025 · strength 0.48
  2. Yan‐Fang Xian · 2 shared papers, 2022–2025 · strength 0.44
  3. Juan Zhang · 2 shared papers, 2022–2025 · strength 0.44
  4. Zhi‐Xiu Lin · 2 shared papers, 2022–2025 · strength 0.44
  5. William Chi Shing Cho · 2 shared papers, 2022–2025 · strength 0.44
  6. Rong Wu · 2 shared papers, 2023–2025 · strength 0.40
  7. Chen Liang · 2 shared papers, 2018–2025 · strength 0.32
  8. Zhen Wang · 2 shared papers, 2018–2025 · strength 0.32
  9. Ying-Yi Li · 2 shared papers, 2018–2025 · strength 0.32
  10. Yulin Wu · 1 shared paper, 2025 · strength 0.28
  11. Jiaqi Tan · 1 shared paper, 2025 · strength 0.27
  12. Kai Qin · 1 shared paper, 2025 · strength 0.27
  13. Jiabin Jin · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.